Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates

Hiran C. Fernando, Alberto De Hoyos, Rodney J. Landreneau, Sebastian Gilbert, William E. Gooding, Percival O. Buenaventura, Neil A. Christie, Chandra Belani, James D. Luketich

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Objective: Treatment options for patients with non-small cell lung cancer who are not surgical candidates or who refuse operation are limited. Radiofrequency ablation represents a potential less invasive option for these patients. Our initial experience with radiofrequency ablation for peripheral, primary non-small cell lung cancer is reported. Methods: We treated 21 tumors in 18 patients. Median age was 75 (range 58-86) years. Cancer stages were I (n = 9), II (n = 2), III (n = 3), and IV (n = 4). Patients with stage IV disease included 3 with recurrence after previous lobectomies and 1 with a synchronous liver metastasis also treated with radiofrequency ablation. Median tumor diameter was 2.8 cm (range 1.2-4.5 cm). Radiofrequency ablation was delivered by minithoracotomy in 2 cases and by a computed tomography-guided percutaneous approach in 16 patients. Computed tomographic and positron emission tomographic scans were used to evaluate recurrence and radiographic response in ablated nodules. Results: One postoperative death occurred from pneumonia after open radiofrequency ablation. Median hospital stay was 2.5 days. A chest tube or pigtail catheter was required in 7 patients (38.9%) for procedure-related pneumothoraces. At a median follow-up of 14 months, 15 patients (83.3%) were alive. Local progression occurred in 8 nodules (38.1%). Mean and median progression-free intervals were 16.8 and 18 months, respectively. For stage I cancers, mean progression-free interval was 17.6 months. Median progression-free interval was not reached. Conclusion: This study demonstrates the feasibility of radiofrequency ablation for small, peripheral non-small cell lung cancer tumors. Local control is comparable to, if not better than, that provided by radiotherapy. Radiofrequency ablation should continue to be evaluated by thoracic surgeons as a noninvasive therapy for the high-risk patient with non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)639-644
Number of pages6
JournalJournal of Thoracic and Cardiovascular Surgery
Volume129
Issue number3
DOIs
StatePublished - Jan 1 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Therapeutics
Neoplasms
Recurrence
Chest Tubes
Feasibility Studies
Pneumothorax
Length of Stay
Pneumonia
Radiotherapy
Thorax
Catheters
Tomography
Electrons
Neoplasm Metastasis
Liver

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. / Fernando, Hiran C.; De Hoyos, Alberto; Landreneau, Rodney J.; Gilbert, Sebastian; Gooding, William E.; Buenaventura, Percival O.; Christie, Neil A.; Belani, Chandra; Luketich, James D.

In: Journal of Thoracic and Cardiovascular Surgery, Vol. 129, No. 3, 01.01.2005, p. 639-644.

Research output: Contribution to journalArticle

Fernando, HC, De Hoyos, A, Landreneau, RJ, Gilbert, S, Gooding, WE, Buenaventura, PO, Christie, NA, Belani, C & Luketich, JD 2005, 'Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates', Journal of Thoracic and Cardiovascular Surgery, vol. 129, no. 3, pp. 639-644. https://doi.org/10.1016/j.jtcvs.2004.10.019
Fernando, Hiran C. ; De Hoyos, Alberto ; Landreneau, Rodney J. ; Gilbert, Sebastian ; Gooding, William E. ; Buenaventura, Percival O. ; Christie, Neil A. ; Belani, Chandra ; Luketich, James D. / Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates. In: Journal of Thoracic and Cardiovascular Surgery. 2005 ; Vol. 129, No. 3. pp. 639-644.
@article{84616a33519a475d8168f2d0840fb9d4,
title = "Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates",
abstract = "Objective: Treatment options for patients with non-small cell lung cancer who are not surgical candidates or who refuse operation are limited. Radiofrequency ablation represents a potential less invasive option for these patients. Our initial experience with radiofrequency ablation for peripheral, primary non-small cell lung cancer is reported. Methods: We treated 21 tumors in 18 patients. Median age was 75 (range 58-86) years. Cancer stages were I (n = 9), II (n = 2), III (n = 3), and IV (n = 4). Patients with stage IV disease included 3 with recurrence after previous lobectomies and 1 with a synchronous liver metastasis also treated with radiofrequency ablation. Median tumor diameter was 2.8 cm (range 1.2-4.5 cm). Radiofrequency ablation was delivered by minithoracotomy in 2 cases and by a computed tomography-guided percutaneous approach in 16 patients. Computed tomographic and positron emission tomographic scans were used to evaluate recurrence and radiographic response in ablated nodules. Results: One postoperative death occurred from pneumonia after open radiofrequency ablation. Median hospital stay was 2.5 days. A chest tube or pigtail catheter was required in 7 patients (38.9{\%}) for procedure-related pneumothoraces. At a median follow-up of 14 months, 15 patients (83.3{\%}) were alive. Local progression occurred in 8 nodules (38.1{\%}). Mean and median progression-free intervals were 16.8 and 18 months, respectively. For stage I cancers, mean progression-free interval was 17.6 months. Median progression-free interval was not reached. Conclusion: This study demonstrates the feasibility of radiofrequency ablation for small, peripheral non-small cell lung cancer tumors. Local control is comparable to, if not better than, that provided by radiotherapy. Radiofrequency ablation should continue to be evaluated by thoracic surgeons as a noninvasive therapy for the high-risk patient with non-small cell lung cancer.",
author = "Fernando, {Hiran C.} and {De Hoyos}, Alberto and Landreneau, {Rodney J.} and Sebastian Gilbert and Gooding, {William E.} and Buenaventura, {Percival O.} and Christie, {Neil A.} and Chandra Belani and Luketich, {James D.}",
year = "2005",
month = "1",
day = "1",
doi = "10.1016/j.jtcvs.2004.10.019",
language = "English (US)",
volume = "129",
pages = "639--644",
journal = "Journal of Thoracic and Cardiovascular Surgery",
issn = "0022-5223",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - Radiofrequency ablation for the treatment of non-small cell lung cancer in marginal surgical candidates

AU - Fernando, Hiran C.

AU - De Hoyos, Alberto

AU - Landreneau, Rodney J.

AU - Gilbert, Sebastian

AU - Gooding, William E.

AU - Buenaventura, Percival O.

AU - Christie, Neil A.

AU - Belani, Chandra

AU - Luketich, James D.

PY - 2005/1/1

Y1 - 2005/1/1

N2 - Objective: Treatment options for patients with non-small cell lung cancer who are not surgical candidates or who refuse operation are limited. Radiofrequency ablation represents a potential less invasive option for these patients. Our initial experience with radiofrequency ablation for peripheral, primary non-small cell lung cancer is reported. Methods: We treated 21 tumors in 18 patients. Median age was 75 (range 58-86) years. Cancer stages were I (n = 9), II (n = 2), III (n = 3), and IV (n = 4). Patients with stage IV disease included 3 with recurrence after previous lobectomies and 1 with a synchronous liver metastasis also treated with radiofrequency ablation. Median tumor diameter was 2.8 cm (range 1.2-4.5 cm). Radiofrequency ablation was delivered by minithoracotomy in 2 cases and by a computed tomography-guided percutaneous approach in 16 patients. Computed tomographic and positron emission tomographic scans were used to evaluate recurrence and radiographic response in ablated nodules. Results: One postoperative death occurred from pneumonia after open radiofrequency ablation. Median hospital stay was 2.5 days. A chest tube or pigtail catheter was required in 7 patients (38.9%) for procedure-related pneumothoraces. At a median follow-up of 14 months, 15 patients (83.3%) were alive. Local progression occurred in 8 nodules (38.1%). Mean and median progression-free intervals were 16.8 and 18 months, respectively. For stage I cancers, mean progression-free interval was 17.6 months. Median progression-free interval was not reached. Conclusion: This study demonstrates the feasibility of radiofrequency ablation for small, peripheral non-small cell lung cancer tumors. Local control is comparable to, if not better than, that provided by radiotherapy. Radiofrequency ablation should continue to be evaluated by thoracic surgeons as a noninvasive therapy for the high-risk patient with non-small cell lung cancer.

AB - Objective: Treatment options for patients with non-small cell lung cancer who are not surgical candidates or who refuse operation are limited. Radiofrequency ablation represents a potential less invasive option for these patients. Our initial experience with radiofrequency ablation for peripheral, primary non-small cell lung cancer is reported. Methods: We treated 21 tumors in 18 patients. Median age was 75 (range 58-86) years. Cancer stages were I (n = 9), II (n = 2), III (n = 3), and IV (n = 4). Patients with stage IV disease included 3 with recurrence after previous lobectomies and 1 with a synchronous liver metastasis also treated with radiofrequency ablation. Median tumor diameter was 2.8 cm (range 1.2-4.5 cm). Radiofrequency ablation was delivered by minithoracotomy in 2 cases and by a computed tomography-guided percutaneous approach in 16 patients. Computed tomographic and positron emission tomographic scans were used to evaluate recurrence and radiographic response in ablated nodules. Results: One postoperative death occurred from pneumonia after open radiofrequency ablation. Median hospital stay was 2.5 days. A chest tube or pigtail catheter was required in 7 patients (38.9%) for procedure-related pneumothoraces. At a median follow-up of 14 months, 15 patients (83.3%) were alive. Local progression occurred in 8 nodules (38.1%). Mean and median progression-free intervals were 16.8 and 18 months, respectively. For stage I cancers, mean progression-free interval was 17.6 months. Median progression-free interval was not reached. Conclusion: This study demonstrates the feasibility of radiofrequency ablation for small, peripheral non-small cell lung cancer tumors. Local control is comparable to, if not better than, that provided by radiotherapy. Radiofrequency ablation should continue to be evaluated by thoracic surgeons as a noninvasive therapy for the high-risk patient with non-small cell lung cancer.

UR - http://www.scopus.com/inward/record.url?scp=14644412387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14644412387&partnerID=8YFLogxK

U2 - 10.1016/j.jtcvs.2004.10.019

DO - 10.1016/j.jtcvs.2004.10.019

M3 - Article

C2 - 15746749

AN - SCOPUS:14644412387

VL - 129

SP - 639

EP - 644

JO - Journal of Thoracic and Cardiovascular Surgery

JF - Journal of Thoracic and Cardiovascular Surgery

SN - 0022-5223

IS - 3

ER -